Alphatec Holdings, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Alphatec reported Q2 2026 total revenue of $214M (up 15% YoY) with surgical revenue of $196M (up 17%). The company achieved non-GAAP adjusted EBITDA of $36M (16.8% margin), expanding 420 bps YoY. Management reaffirmed full-year 2026 revenue guidance at ~$882M but raised adjusted EBITDA guidance from $134M to $140M, citing strong case volume growth (20%), net new surgeon user growth (24%), and positive free cash flow generation. Cash position decreased to $119M from $161M at year-end 2025.
Why this rating
Strong organic growth metrics (15-17% revenue, 20% case volume) and EBITDA margin expansion are operationally positive. However, company remains unprofitable on GAAP basis ($26M net loss Q2), maintains high debt, and $119M cash is modest for a $1.3B company. Material but not transformational.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.